Index to Volume 13

Author Index

– A –

Abou-Shala N: see Self TH, et al, 590
Abraham I: see Sketris IS, et al, 658
ACCP Fourth Annual Winter Practice and Research Forum—Abstracts and Index of Authors, 673
ACCP Position Statement: Pharmacists and the Pharmaceutical Industry: Guidelines for Ethical Interactions, 531
ACCP White Paper: Ethical Issues Related to Clinical Pharmacy Research, 523
ACCP White Paper: Women as Research Subjects, 534
ACCP: Guidelines for Therapeutic Interchange, 252
ACCP: Template for the Evaluation of a Clinical Pharmacist, 661
ACCP: The Strategic Plan of the American College of Clinical Pharmacy, 1993, 257
Ackerman BH: see Monaghan MS, et al, 60
Ackerman BH: see Olsen KM, et al, 229
Alexander VL: see Guay DR, et al, 54S
Alloway RR: see Self TH, et al, 590
Applegate WB: see Pool PE, et al, 487
Asher MA: see Leonard TM, et al, 378
Assaf AR: see Barbour MM, et al, 239
Assaf AR: see Hume AL, et al, 244

– B –

Baker A: see Nimmo CR, 408
Bannick-Mohrland SD: see O'Connell MB, et al, 135
Barbour MM, Hume AL, Assaf AR, Carleton RA: The Drug Data Base of the Pawtucket Heart Health Program: Development and Description, 239
Barbour MM: see Hume AL, et al, 244
Barriere SL: Therapeutic Decisions: Assessing Clinical Fit, 18S
Bartos L: see Cordaro JA, et al, 369
Belliveau P, Hickingbotham N, Maderazo EG, Mazens-Sullivan M, Robinson A: Institution-Specific Patterns of Infection and Gram's Stain as Guides for Empiric Treatment of Patients Hospitalized With Typical Community-Acquired Pneumonia, 396
Bhatt RH: see Micali G, et al, 386
Bhatt-Mehta V, Deluga KS: Fetal Exposure to Lisinopril: Neonatal Manifestations and Management, 515
Bisson C, St.-Laurent M, Michaud JT, LeBel M: Pharmacokinetics and Pharmacodynamics of Ranitidine and Famotidine in Healthy Elderly Subjects: A Double-Blind, Placebo-Controlled Comparison, 3
Bond CA: see Raehl CL, et al, 618
Boucher BA: see Hess MM, et al, 602
Brown D: see Laizure SC, et al, 471
Brushwood DB: Pharmaco-legal Considerations in the Clinical Use of Decongestants, 135S
Bui B: see Seifert CF, et al, 391
Bussey HI: Ode to Beer Cans, Canoes, House Trailers, and Jimmy Buffet: Author's Reply, 160

– C –

Cady WJ: see Pool PE, et al, 487
Caltabiano L: see Micali G, et al, 386
Carleton RA: see Barbour MM, et al, 239
Carleton RA: see Hume AL, et al, 244
Carter BL, Noyes MA, Demmler RW: Differences in Serum Concentrations of and Responses to Generic Verapamil in the Elderly, 359
Carter JR: see Thompson DF, 37
Chan E, Montgomery PA: Administration of Insulin by Continuous Ambulatory Peritoneal Dialysis, 455
Charland SL: see Spinler SA, et al, 68
Chitwood KK, Heim-Duthoy KL: Immunosuppressive Properties of Calcium Channel Blockers, 447
Chow MSS: Assessing the Treatment of Congestive Heart Failure: Diuretics, Vasodilators, and Angiotensin-Converting Enzyme Inhibitors, 82S
Chow MSS: Introduction to Congestive Heart Failure Supplement, 71S
Clarens DM, Kelly KJ, Gilliland SS, Kohls PK, Nahum A, Vance-Bryan K: A Retrospective Analysis of Long-Term Use of Nondepolarizing Neuromuscular Blocking Agents in the Intensive Care Unit, and Guidelines for Drug Selection, 647
Clarke WR, Horn JR, Kawabori I, Gurtel S: Potentially Serious Drug Interactions Secondary to High-Dose Diltiazem Used in the Treatment of Pulmonary Hypertension, 402
Cleary JD: see Tidwell BH, 165
Colomaio R: see Cordaro JA, et al, 369
Constantine GH: Ode to Beer Cans, Canoes, House Trailers, and Jimmy Buffet: A Commentary, 159
Cook B: see Micali G, et al, 386
Cooper MR: see Thibault A, et al, 656
Cordaro JA, Morse GD, Bartos L, Gugino LJ, Maliszewski M, Colomaio R, Shelton M, O'Donnell A, Hewitt R: Zidovudine Pharmacokinetics in HIV-Positive Women During Different Phases of the Menstrual Cycle, 369
Covington TR: see Guay DR, et al, 54S
Crawford SY: see Schumock GT, et al, 668
Croce MA: see Hess MM, et al, 602

– D –

Danziger LH: see Fish DN, 415
Danziger LH: see Fish DN, 543
Danziger LH: see Gubbins PO, et al, 110
Dean AD: see Derby LE, et al, 353
Dean AD: see Jick H, et al, 212
Dean AD: see Jick SS, et al, 461
Deluga KS: see Bhatt-Mehta V, 515
Demmler RW: see Carter BL, et al, 359
Derby LE, Gutthann SP, Jick H, Dean AD: Liver Disorders in Patients Receiving Chlorpromazine or Isoniazid, 353
Derby LE: see Jick H, et al, 212
Destache CJ: see Massoomi F, et al, 46
Distefano G: see Micali G, et al, 386
Donahue DJ: see Laizure SC, et al, 471
Dowse R: see Kanfer I, 116S
Dudley MN: Maximizing Patient Outcomes of Antiinfective Therapy, 29S
Dwinell AM: see O'Connell MB, et al, 135

– E –

Ereshefsky L: see Thornberg SA, 510
Esterbrooks DJ: see Mohiuddin SM, et al, 476

– F –

Fabian TC: see Hess MM, et al, 602
Farmer C: see Monaghan MS, et al, 60
Figg WD: see Thibault A, et al, 656
Fireman P: Pathophysiology and Pharmacotherapy of Common Upper Respiratory Diseases, 101S
Fischer JH: see Micali G, et al, 386
Fish DN, Danziger LH: Neglected Pathogens: Bacterial Infections in Persons With Human Immunodeficiency Virus Infection—A Review of the Literature (First of Two Parts), 415
Fish DN, Danziger LH: Neglected Pathogens: Bacterial Infections in Persons With Human Immunodeficiency Virus Infection—A Review of the Literature (Second of Two Parts), 543
Fletcher CV: Current Perspectives on Antiretroviral Therapy, 627
Forrest A: see Paladino JA, et al, 504
Foster, Jr, MT: Diagnosis and Treatment of Community-Acquired and Hospital-Acquired Pneumonia, 45S
Furey SA, Vargas R, McMahon FG: Renovascular Effects of Nonprescription Ibuprofen in Elderly Hypertensive Patients With Mild Renal Impairment, 143

– G –

Gammaitoni A: see Spinler SA, et al, 68
Generali JA, Klutman NE: Criteria for the Use of Intravenous Ofloxacin in Hospitalized Adult Patients: Drug Use Evaluation Guidelines, 58S
Gentry LO: Prescribing Considerations in Fluoroquinolone Therapy, 39S
Gericke KR: Possible Interaction Between Warfarin and Fluconazole, 508
Gibaldi M: Ethnic Differences in the Assessment and Treatment of Disease, 170
Gibaldi M: Human Gene Therapy, 79
Gibaldi M: Prescription Drugs and Health Care Reform, 583
Gibaldi Milo: Anatomy of an Antibody, and Related Misadventures in Developing an Effective Treatment for Septic Shock: 302
Gilliland SS: see Clarens DM, et al, 647
Giusto DA: see Schumock GT, et al, 668
Givner M: see Sketris IS, et al, 658
Goodwin SD: *Pneumocystis carinii* Pneumonia in Human Immunodeficiency Virus-Infected Infants and Children, 640
Gosland MP: see Lum BL, et al, 88
Gottlieb JE: see Mehra IV, et al, 128
Guay DR, Covington TR, Alexander VL: Developing Drug Use Evaluation Criteria for Parenteral Fluoroquinolones, 54S
Gubbins PO, Piscitelli SC, Danziger LH: Candidal Urinary Tract Infections: A Comprehensive Review of Their Diagnosis and Management, 110
Gugino LJ: see Cordaro JA, et al, 369
Gupta NC: see Mohiuddin SM, et al, 476
Gurtel S: see Clarke WR, et al, 402
Gutthann SP: see Derby LE, et al, 353

– H –

Hall PD: Immunomodulation With Intravenous Immunoglobulin, 564
Hamelin BA, Moore N, Knupp CA, Ruel M, Vallée F, LeBel M: Cefepime Pharmacokinetics in Cystic Fibrosis, 465
Hatton J, Luer MS, Rapp RP: Growth Factors in Nutritional Support, 17
Hawkins DW: Who Decides The Future of Pharmacy Education and Practice? Commentary on Ode to Beer Cans, Canoes, House Trailers, and Jimmy Buffet, 162
Headlee DJ: see Thibault A, et al, 656
Heilker GM: see Self TH, et al, 590
Heim-Duthoy KL: see Chitwood KK, 447
Heiselman DE: see Hulisz DT, et al, 64
Hendeles L: Efficacy and Safety of Antihistamines and Expectorants in Nonprescription Cough and Cold Preparations, 154
Hendeles L: see Weinberger MM, 598
Hendeles L: Selecting a Decongestant, 129S
Hepler CD: Pharmaceutical Care and Specialty Practice, 64S
Hess MM, Boucher BA, Laizurem SC, Stevens RC, Sanders PL, Janning SW, Croce MA, Fabian TC: Trimethoprim-Sulfamethoxazole Pharmacokinetics in Trauma Patients, 602
Hewitt R: see Cordaro JA, et al, 369
Hickingbotham N: see Belliveau P, et al, 396
Hilleman DE: Assessing the Treatment of Congestive Heart Failure: Inotropic Agents and Calcium Channel Blockers, 88S
Hilleman DE: see Mohiuddin SM, et al, 476
Hitzenberger G: see Kovarik JM, et al, 613
Hooton TM: see Tartaglione TA, 189
Horn JR: see Clarke WR, et al, 402
Hricik JG: see Johnson DA, 110S
Htan EYH: see Shalansky KF, et al, 233
Huber SL: Changes in Fluoroquinolone Antibiotics, 1S
Hulisz DT, Welko JR, Heiselman DE.: Sinus Arrest Associated With Continuous-Infusion Cimetidine, 64
Hume AL, Barbour MM, Willey CJ, Assaf AR, Lapane KL, Carleton RA: Changing Trends in Antihypertensive Therapy in Two New England Communities During the 1980s, 244
Hume AL: see Barbour MM, et al, 239
Hurwitz J: see Spinler SA, et al, 68
Hutchinson RA: see Schumock GT, et al, 668
Index to Volume 13, 1993, and Acknowledgement of Academic Reviewers for 1993, 694

– I –

Izzo, Jr, JL: see Perreault MM, et al, 149

– J –

Jacobson PA: see Levinson ML, 168
Jann MW: The One Who Dies With the Most Letters Behind His Name Wins, 519
Janning SW: see Hess MM, et al, 602
Jeffries S: Splitting Hairs, 169
Jeffries S: Too, Too Much, 301
Jeffries Sarah: Authors' Affiliations, 520
Jenne JW: Reassessing the Therapeutic Range for Theophylline on Laboratory Report Forms: Another Viewpoint, 595

Jewesson P: see Nimmo CR, 408
Jick H, Derby LE, Rodríguez LAG, Jick SS, Dean AD: Nonsteroidal Antiinflammatory Drugs and Certain Rare, Serious Adverse Events: A Cohort Study, 212
Jick H: see Derby LE, et al, 353
Jick H: see Jick SS, et al, 461
Jick SS, Jick H, Dean AD: A Follow-Up Safety Study of Ciprofloxacin Users, 461
Jick SS: see Jick H, et al, 212
Johnson DA, Hricik JG: The Pharmacology of α-Adrenergic Decongestants, 110S
Johnston A: see Kovarik JM, et al, 613
Just PM: Overview of the Fluoroquinolone Antibiotics, 4S

– K –

Kanfer I, Dowse R, Vuma V: Pharmacokinetics of Oral Decongestants, 116S
Kastens DJ: see Seifert CF, et al, 391
Kaubisch S: see Lum BL, et al, 88
Kawabori I: see Clarke WR, et al, 402
Kazierad DJ: see Perreault MM, et al, 149
Kelly KJ: see Clarens DM, et al, 647
Kelso TM: see Self TH, et al, 590
Klem SA: see Leonard TM, et al, 378
Knupp CA: see Hamelin BA, et al, 465
Kohls PK: see Clarens DM, et al, 647
Koronkowski MJ: see Sudduth SL, 309
Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K: Bioequivalence of Soft Gelatin Capsules and Oral Solution of a New Cyclosporine Formulation, 613
Kutz K: see Kovarik JM, et al, 613

– L –

Laizure SC, Miller JH, Stevens RC, Donahue DJ, Laster RE, Brown D: The Disposition and Cerebrospinal Fluid Penetration of Morphine and Its Two Major Glucuronidated Metabolites in Adults Undergoing Lumbar Myelogram, 471
Laizurem SC: see Hess MM, et al, 602
Lapane KL: see Hume AL, et al, 244
Laster RE: see Laizure SC, et al, 471
LeBel M: see Bisson C, et al, 3
LeBel M: see Hamelin BA, et al, 465
Leff RD: see Leonard TM, et al, 378
Leier CV: Clinical Trial Strategies and Future Challenges in the Investigation of Human Congestive Heart Failure, 94S
Leonard TM, Klem SA, Asher MA, Rapoff MA, Leff RD: Relationship Between Pain Severity and Serum β-Endorphin Levels in Postoperative Patients, 378
Levinson ML, Jacobson PA: Treatment and Prophylaxis of Cytomegalovirus Disease: Authors' Reply, 168
Levy M, Spino M: Neonatal Withdrawal Syndrome: Associated Drugs and Pharmacologic Management, 202
Lucas DS: see Seifert CF, et al, 391
Luer MS: see Hatton J, et al, 17
Lum BL, Gosland MP, Kaubisch S, Sikic BI: Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene, 88
Lyster DM: see Shalansky KF, et al, 233

– M –

Ma FH: see Olsen KM, et al, 229
Maderazo EG: see Belliveau P, et al, 396
Magill HL: see Rodman JH, et al, 10
Maliszewski M: see Cordaro JA, et al, 369
Maloley PA: see Meyers DG, 574
Mamdani F: see Nimmo CR, 408
Maneval D: see Rodman JH, et al, 10
Marchbanks CR: Drug-Drug Interactions With Fluoroquinolones, 23S
Massoomi F, Savage J, Destache CJ: Omeprazole: A Comprehensive Review, 46
Mazens-Sullivan M: see Belliveau P, et al, 396
McCarty DL: see Seifert CF, et al, 391
McCue JD: Urinary Tract Infections in the Elderly, 51S
McCullough JM: see Travis BE, 28
McKenney JM: Understanding and Treating Dyslipidemia Associated With Noninsulin-Dependent Diabetes Mellitus and Hypertension, 340
McMahon FG, Vargas R: Can Garlic Lower Blood Pressure? A Pilot Study, 406
McMahon FG: see Furey SA, et al, 143
Mehra IV, Gottlieb JE, Nash DB: Monoclonal Antibody Therapy for Gram-Negative Sepsis: Principles, Applications, and Controversies. 128
Mehra IV, Wilson MD: The Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction, 440
Merritt GJ, Slade JB: Influence of Hyperbaric Oxygen on the Pharmacokinetics of Single-Dose Gentamicin in Healthy Volunteers, 382
Meyers DG, Maloley PA: The Antioxidant Vitamins: Impact on Atherosclerosis, 574
Micali G, Bhatt RH, Distefano G, Caltabiano L, Cook B, Fischer JH, Solomon LM, West DP: Evaluation of Transdermal Theophylline Pharmacokinetics in Neonates, 386
Michaud JT: see Bisson C, et al, 3
Miller JH: see Laizure SC, et al, 471
Mohiuddin SM, Esterbrooks DJ, Gupta NC, Hilleman DE: Safety of Different Dosages of Intravenous Adenosine Used in Conjunction With Diagnostic Myocardial Imaging Techniques, 476
Monaghan MS, Ackerman BH, Olsen KM, Farmer C, Pappas AA: The Use of Δ Osmolality to Predict Serum Isopropanol and Acetone Concentrations, 60
Montgomery PA: see Chan E, 455
Moore N: see Hamelin BA, et al, 465
Morse GD: see Cordaro JA, et al, 369
Mouat B: see Shalansky KF, et al, 233
Mroczek WJ: see Ruddy MC, et al, 224
Mueller EA: see Kovarik JM, et al, 613
Munger MA, Nara AR, Pospisil RA, Stoddard GJ, Schleman M: Invasive Pharmacodynamic Characterization of Combined Ibopamine and Calcium Blocker Therapy for Heart Failure, 218
Myers CE: see Thibault A, et al, 656

– N –

Nagel KM, Holstad SG, Isenberg KE: Oligonucleotide Pharmacotherapy: An Antigene Strategy, 177
Nahum A: see Clarens DM, et al, 647
Nara AR: see Munger MA, et al, 218
Nash DB: see Mehra IV, et al, 128
Nicol D: see Sketris IS, et al, 658
Nightingale CH: Pharmacokinetic Considerations in Quinolone Therapy, 34S

Nightingale CH: see Sullivan MC, et al, 607
Nimmo CR, Mamdani F, Baker A, Jewesson P: Development and Implementation of Simplified Aminoglycoside Empiric Dosing Guidelines, 408
Noyes MA: see Carter BL, et al, 359

– O –

O'Connell MB, Wong MO, Bannick-Mohrland SD, Dwinell AM: Accuracy of 2- and 8-Hour Urine Collections for Measuring Creatinine Clearance in the Hospitalized Elderly, 135
O'Donnell A: see Cordaro JA, et al, 369
Olsen KM, Ma FH, Ackerman BH, Stull RE: Low-Volume Whole Bowel Irrigation and Salicylate Absorption: A Comparison With Ipecac-Charcoal, 229
Olsen KM: see Monaghan MS, et al, 60
Onorato L: see Sketris IS, et al, 658

– P –

Paladino JA, Forrest A, Wilton JH: Predictors of Trough Concentrations of Oral Ciprofloxacin, 504
Panel Discussion, 143S
Pappas AA: see Monaghan MS, et al, 60
Partipilo ML, Woster PS: The Role of *Helicobacter pylori* in Peptic Ulcer Disease, 330
Patterson JH, Adams, Jr, KF: Pathophysiology of Heart Failure, 73S
Peloquin CA: Mycobacterial Infections, 634
Perreault MM, Kazierad DJ, Wilton JH, Izzo, Jr, JL: The Effect of Isradipine on Theophylline Pharmacokinetics in Healthy Volunteers, 149
Piscitelli SC: see Gubbins PO, et al, 110
Pitterle ME: see Raehl CL, et al, 618
Plaisance KI: see Yurkowski PJ, 494
Pool PE, Applegate WB, Woehler T, Sandall P, Cady WJ: A Randomized, Controlled Trial Comparing Diltiazem, Hydrochlorothiazide, and Their Combination in the Therapy of Essential Hypertension, 487
Pospisil RA: see Munger MA, et al, 218
Prindiville SA: see Thibault A, et al, 656

– Q –

Quinn JP: *Pseudomonas aeruginosa*-Acquired Resistance to Imipenem-Cilastatin: Author's Reply, 166
Quintiliani R: see Sullivan MC, et al, 607

– R –

Raehl CL, Bond CA, Pitterle ME: Ambulatory Pharmacy Services Affiliated With Acute Care Hospitals, 618
Rapoff MA: see Leonard TM, et al, 378
Rapp RP: see Hatton J, et al, 17
Razzaghi A: see Wu F, et al, 72
Reed KA: see Tornatore KM, et al, 481
Robinson A: see Belliveau P, et al, 396
Rodman JH, Maneval D, Magill HL, and Sunderland M: Measurement of Tc-99m DTPA Serum Clearance for Estimating Glomerular Filtration Rate in Children With Cancer, 10
Rodríguez LAG: see Jick H, et al, 212
Rodvold KA: Pharmacotherapy of Infectious Complications in Patients With Acquired Immunodeficiency Syndrome, 626
Ruddy MC, Mroczek WJ: Comparison of Ramipril and Enalapril in Patients With Essential Hypertension, 224
Ruel M: see Hamelin BA, et al, 465

– S –

Sandall P: see Pool PE, et al, 487
Sanders PL: see Hess MM, et al, 602
Sartor AO: see Thibault A, et al, 656
Savage J: see Massoomi F, et al, 46
Scheife RT: Editorial, Changes in Pharmacotherapy, 1
Schleman M: see Munger MA, et al, 218
Schumock GT, Crawford SY, Giusto DA, Hutchinson RA: Evaluating the Performance of Clinical Pharmacy Faculty: Putting the ACCP Template to Use, 668
Seifert CF, Lucas DS, Vondracek TG, Kastens DJ, McCarty DL, Bui B: Patterns of Acetaminophen Use in Alcoholic Patients, 391
Self TH, Heilker GM, Alloway RR, Kelso TM, Abou-Shala N: Reassessing the Therapeutic Range for Theophylline on Laboratory Report Forms: The Importance of 5–15 µg/ml, 590
Shalansky KF, Htan EYH, Lyster DM, Mouat B, Tweeddale MG: In Vitro Evaluation of the Effect of Metered-Dose Inhaler Administration Technique on Aerosolized Drug Delivery, 233
Sikic BI: see Lum BL, et al, 88
Sketris IS, Onorato L, Yatscoff RW, Givner M, Nicol D, Abraham I: Eight Days of Cyclosporine Overdose: A Case Report, 658
Slade JB: see Merritt GJ, et al, 382
Smith CL: see Wagner ML, et al, 500
Solomon LM: see Micali G, et al, 386
Souney PF: see Wu F, et al, 72
Spinler SA, Gammaitoni A, Charland SL, Hurwitz J: Propafenone-Theophylline Interaction, 68
Spino M: see Levy M, 202
St.-Laurent M: see Bisson C, et al, 3
Stevens RC: see Hess MM, et al, 602
Stevens RC: see Laizure SC, et al, 471
Stoddard GJ: see Munger MA, et al, 218
Stull RE: see Olsen KM, et al, 229
Sudduth SL, Koronkowski MJ: Finasteride: The First 5α-Reductase Inhibitor, 309
Sullivan MC, Nightingale CH, Quintiliani R, Sweeney K: Comparison of the Pharmacokinetic and Pharmacodynamic Activity of Piperacillin and Mezlocillin, 607
Sunderland M: see Rodman JH, et al, 10
Sweeney K: see Sullivan MC, et al, 607

– T –

Talbert RL: Ethics in Clinical Pharmacy Practice and Research: An Introduction, 521
Tartaglione TA, Hooton TM: The Role of Fluoroquinolones in Sexually Transmitted Diseases, 189
Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE: Anaphylactoid Reaction With Suramin, 656
Thompson DF, Carter JR: Drug-Induced Gynecomastia, 37
Thornberg SA, Ereshefsky L: Neuroleptic Malignant Syndrome Associated With Clozapine Monotherapy, 510
Tidwell BH, Cleary JD: *Pseudomonas aeruginosa*-Acquired Resistance to Imipenem-Cilastatin: Commentary on Clinical Implications of Antibiotic Resistance, 165

Tornatore KM, Reed KA, Venuto RC: Racial Differences in the Pharmacokinetics of Methylprednisolone in Black and White Renal Transplant Recipients, 481
Travis BE, McCullough JM: Pharmacotherapy of Preterm Labor, 28
Tweeddale MG: see Shalansky KF, et al, 233

– V –

Vallée F: see Hamelin BA, et al, 465
Vance-Bryan K: see Clarens DM, et al, 647
Vargas R: see Furey SA, et al, 143
Vargas R: see McMahon FG, 406
Venuto RC: see Tornatore KM, et al, 481
Vondracek TG: see Seifert CF, et al, 391

– W –

Wagner BKJ: see Wagner ML, et al, 500
Wagner ML, Wagner BKJ, Smith CL: Faculty Have Few Incentives for Becoming Board Certified in Pharmacotherapy, 500
Weinberger MM, Hendeles L: Reassessing the Therapeutic Range for Theophylline: Another Perspective, 598
Welko JR: see Hulisz DT, et al, 64
West DP: see Micali G, et al, 386
Willey CJ: see Hume AL, et al, 244
Wilson MD: see Mehra IV, 440
Wilton JH: see Paladino JA, et al, 504
Wilton JH: see Perreault MM, et al, 149
Woehler T: see Pool PE, et al, 487
Wong MO: see O'Connell MB, et al, 135
Woster PS: see Partipilo ML, 330
Wu F, Razzaghi A, Souney PF: Seizure After Lidocaine for Bronchoscopy: Case Report and Review of the Use of Lidocaine in Airway Anesthesia, 72

– Y –

Yatscoff RW: see Sketris IS, et al, 658
Yee GC: Treatment and Prophylaxis of Cytomegalovirus Disease: A Commentary, 167
Yurkowski PJ, Plaisance KI: Prevention of Auditory Sequelae in Pediatric Bacterial Meningitis: A Meta-Analysis, 494

– Z –

Zarowitz BJ, Vlasses PH, Dukes GE, Gal P, Miller WA, Porter WC, Rush DR, Schneider P, Talbert RL: Pharmacotherapy Specialty Certification Examination. IV. 1992 Results and Process Modifications, Including Recertification, 262

– A –

Abstracts and Index of Authors—ACCP Fourth Annual Winter Practice and Research Forum, 673
Accuracy of 2- and 8-hour urine collections for measuring creatinine clearance in the hospitalized elderly, 135
Acetaminophen, patterns of use in alcoholic patients, 391
Acetone and isopropanol serum concentrations, the use of Δ osmolality to predict, 60
Acknowledgement of Academic Reviewers for 1993, 694
Acquired immunodeficiency syndrome, pharmacotherapy of infectious complications in patients with, 626
Adenosine, intravenous, safety of different dosages of used in conjunction with diagnostic myocardial imaging techniques, 476
Ambulatory pharmacy services affiliated with acute care hospitals, 618
Aminoglycoside empiric dosing guidelines, development and implementation of, 408
Anaphylactoid reaction with suramin, 656
Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock, 302
Angiotensin-converting enzyme inhibitors, diuretics, and vasodilators: assessing the treatment of congestive heart failure, 82S
Angiotensin-converting enzyme inhibitors, the use of after acute myocardial infarction, 440
Antihistamines and expectorants in nonprescription cough and cold preparations, efficacy and safety of, 154
Antihypertensive therapy, changing trends in two New England communities during the 1980s, 244
Antiinfective therapy, maximizing patient outcomes in, 29S
Antiretroviral therapy, current perspectives on, 627
Atherosclerosis, impact of the antioxidant vitamins, 574
Auditory sequelae in pediatric bacterial meningitis, prevention of: a meta-analysis, 494
Authors' affiliations, 519, 520

– B –

Bacterial infections in persons with human immunodeficiency virus infection (neglected pathogens): A review of the literature (first and second of two parts), 415, 543
Bacterial meningitis, pediatric, prevention of auditory sequelae in: a meta-analysis, 494
Board certification in pharmacotherapy, faculty have few incentives for pursuing, 500
Bronchoscopy, seizure after lidocaine for: case report and review of the use of lidocaine in airway anesthesia, 72

– C –

Calcium channel blockers and inotropic agents, assessing the treatment of congestive heart failure with, 88S
Calcium channel blockers, immunosuppressive properties of, 447
Cancer, measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with, 10
Candidal urinary tract infections: a comprehensive review of their diagnosis and management, 110
Cefepime pharmacokinetics in cystic fibrosis, 465
Changes at Pharmacotherapy, 1
Chlorpromazine or isoniazid, liver disorders in patients receiving, 353
Cimetidine, sinus arrest associated with continuous-infusion, 64
Ciprofloxacin, a follow-up safety study of, 461
Ciprofloxacin, predictors of trough concentrations of oral, 504
Clinical pharmacy faculty: evaluating the performance of, putting the ACCP template to use, 668
Clozapine monotherapy, neuroleptic malignant syndrome associated with, 510
Community-acquired pneumonia, institution-specific patterns of infection and Gram's stain as guides for empiric treatment of patients hospitalized with typical, 396
Comparison of ramipril and enalapril in patients with essential hypertension, 224
Congestive heart failure, assessing the treatment of with diuretics, vasodilators, and angiotensin-converting enzyme inhibitors, 82S
Congestive heart failure, assessing the treatment of with inotropic agents and calcium channel blockers, 88S
Congestive heart failure, clinical trial strategies and future challenges in the investigation of human, 94S
Creatinine clearance, accuracy of 2- and 8-hour urine collections for measuring in the hospitalized elderly, 135
Cyclosporine, bioequivalence of soft gelatin capsules and oral solution of a new formulation, 613
Cyclosporine, eight days of overdose: a case report, 658
Cystic fibrosis, cefepime pharmacokinetics in, 465
Cytomegalovirus disease, treatment and prophylaxis of: a commentary, 167

– D –

Decongestant, selecting a, 129S
Decongestants, clinical use of, panel discussion, 143S
Decongestants, pharmaco-legal considerations in the clinical use of, 135S
Decongestants, pharmacokinetics of oral, 116S
Decongestants, the pharmacology of α-adrenergic, 110S
Delta Osmolality to predict serum isopropanol and acetone concentrations, the use of, 60
Diagnosis and treatment of community-acquired and hospital-acquired pneumonia, 45S
Diltiazem and hydrochlorothiazide: a randomized, controlled trial comparing each in the therapy of essential hypertension, 487
Diltiazem, potentially serious drug interactions secondary to high-dose when used in the treatment of pulmonary hypertension, 402
Diuretics, vasodilators, and angiotensin-converting enzyme inhibitors: assessing the treatment of congestive heart failure, 82S

Drug use evaluation criteria for parenteral fluoroquinolones, developing, 54S
Drug-drug interactions with fluoroquinolones, 23S
Drug-induced gynecomastia, 37
Dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension, understanding and treating, 340

– E –

Editorial, Changes at Pharmacotherapy, 1
Enalapril and ramipril, comparison of in patients with essential hypertension, 224
Endorphin levels and pain severity in postoperative patients, relationship between, 378
Ethical issues related to clinical pharmacy research (an ACCP position paper), 523
Ethics in clinical pharmacy practice and research: an introduction, 521
Ethnic differences in the assessment and treatment of disease, 170
Expectorants and antihistamines in nonprescription cough and cold preparations, efficacy and safety of, 154

– F –

Famotidine and ranitidine, pharmacokinetics and pharmacodynamics of in healthy elderly subjects, 3
Finasteride: the first 5α-reductase inhibitor, 309
Fluconazole and warfarin, possible interaction between, 508
Fluoroquinolone antibiotics, overview of the, 4S
Fluoroquinolones, drug-drug interactions with, 23S
Fluoroquinolones, role of in sexually transmitted diseases, 189

– G –

Garlic, can it lower blood pressure? A pilot study, 406
Gene therapy, human, 79
Gentamicin, influence of hyperbaric oxygen on the pharmacokinetics of single-dose in healthy volunteers, 382
Glomerular filtration rate, measurement of Tc-99m DTPA serum clearance for estimating in children with cancer, 10
Gram-negative sepsis, monoclonal antibody therapy for: principles, applications, and controversies, 128
Growth factors in nutritional support, 17
Guidelines for therapeutic interchange (ACCP position paper), 252
Gynecomastia, drug-induced, 37

– H –

Health care reform and prescription drugs, 583
Heart failure, invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for, 218
Heart failure, pathophysiology of, 73S
Helicobacter pylori, the role of in peptic ulcer disease, 330
Human gene therapy, 79
Human immunodeficiency virus infection, bacterial infections in persons with: a review of the literature (first and second of two parts), 415, 543
Human immunodeficiency virus-infected infants and children, *Pneumocystis carinii* pneumonia in, 640
Hydrochlorothiazide and diltiazem: a randomized, controlled trial comparing each in the therapy of essential hypertension, 487
Hyperbaric oxygen, influence of on the pharmacokinetics of single-dose gentamicin in healthy volunteers, 382

– I –

Ibopamine and calcium blocker, invasive pharmacodynamic characterization of combined therapy for heart failure, 218
Ibuprofen, nonprescription, renovascular effects of in elderly hypertensive patients with mild renal impairment, 143
Immunoglobulin, intravenous, immunomodulation with, 564
Immunosuppressive properties of calcium channel blockers, 447
Inotropic agents and calcium channel blockers, assessing the treatment of congestive heart failure with, 88S
Insulin, administration of by continuous ambulatory peritoneal dialysis, 455
Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure, 218
Isoniazid or chlorpromazine, liver disorders in patients receiving, 353
Isopropanol and Acetone serum concentrations, the use of Δ osmolality to predict, 60
Isradipine, effect of on theophylline pharmacokinetics in healthy volunteers, 149

– L –

Lidocaine for bronchoscopy, seizure after: case report and review of the use of lidocaine in airway anesthesia, 72
Lisinopril, fetal exposure to, neonatal manifestations and management, 515
Liver disorders in patients receiving chlorpromazine or isoniazid, 353

– M –

Maximizing patient outcomes of antiinfective therapy, 29S
Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer, 10
Menstrual cycle, zidovudine pharmacokinetics in HIV-positive women during different phases of the, 369
Metered-dose inhaler administration technique, in vitro evaluation of the effect of on aerosolized drug delivery, 233
Methylprednisolone, racial differences in the pharmacokinetics of in black and white renal transplant recipients, 481
Mezlocillin and piperacillin, comparison of the pharmacokinetic and pharmacodynamic activity of, 607
Molecular targets in oncology: implications of the multidrug resistance gene, 88
Monoclonal antibody therapy for Gram-negative sepsis: principles, applications, and controversies, 128

Morphine and its two major glucuronidated metabolites, disposition and cerebrospinal fluid penetration of in adults undergoing lumbar myelogram, 471
Multidrug resistance gene, implications of in oncology, 88
Mycobacterial infections, 634

– N –

Neonatal withdrawal syndrome: associated drugs and pharmacologic management, 202
Neuroleptic malignant syndrome associated with clozapine monotherapy, 510
Nondepolarizing neuromuscular blocking agents in the intensive care unit, A retrospective analysis of long-term use of and guidelines for drug selection, 647
Noninsulin-dependent diabetes mellitus and hypertension, understanding and treating the dyslipidemia associated with, 340
Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study, 212
Nutritional support, growth factors in, 17

– O –

Ode to beer cans, canoes, house trailers, and Jimmy Buffet: a commentary, 159
Ode to beer cans, canoes, house trailers, and Jimmy Buffet: author's reply, 160
Ode to beer cans, canoes, house trailers, and Jimmy Buffet: who decides the future of pharmacy education and practice? Commentary on, 162
Ofloxacin, intravenous, criteria for the use of in hospitalized adult patients: drug use evaluation guidelines, 58S
Oligonucleotide pharmacotherapy: an antigene strategy, 177
Omeprazole: a comprehensive review, pharmacology, toxicology, clinical applications, 46
Oncology, implications of the multidrug resistance gene in, 88
Overview of the fluoroquinolone antibiotics, 4S

– P –

Pain severity and serum β-endorphin levels in postoperative patients, relationship between, 378
Patient outcomes, maximizing in antiinfective therapy, 29S
Patterns of infection, institution-specific, and Gram's stain as guides for empiric treatment of patients hospitalized with typical community-acquired pneumonia, 396
Pawtucket Heart Health Program, the drug data base of the, development and description, 239
Peptic ulcer disease, the role of *Helicobacter pylori* in, 330
Pharmaceutical care and specialty practice, 64S
Pharmacists and the pharmaceutical industry: guidelines for ethical interactions (an ACCP position statement), 531
Pharmaco-legal considerations in the clinical use of decongestants, 135S
Pharmacokinetic considerations in quinolone therapy, 34S
Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison, 3
Pharmacotherapy of preterm labor, 28
Pharmacotherapy specialty certification examination. IV. 1992 Results and process modifications, including recertification, 262
Piperacillin and mezlocillin, comparison of the pharmacokinetic and pharmacodynamic activity of, 607
Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children, 640
Pneumonia, diagnosis and treatment of community-acquired and hospital-acquired, 45S
Prescribing considerations in fluoroquinolone therapy, 39S
Prescription drugs and health care reform, 583
Preterm labor, pharmacotherapy of, 28
Propafenone-theophylline interaction, 68
Pseudomonas aeruginosa-acquired resistance to imipenem-cilastatin: author's reply, 166
Pseudomonas aeruginosa-acquired resistance to imipenem-cilastatin: commentary on clinical implications of antibiotic resistance, 165

– R –

Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients, 481
Ramipril and enalapril, comparison of in patients with essential hypertension, 224
Ranitidine and famotidine, pharmacokinetics and pharmacodynamics of in healthy elderly subjects, 3
Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment, 143

– S –

Salicylate absorption: comparison of low-volume whole bowel irrigation and ipecac-charcoal, 229
Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia, 72
Septic shock, anatomy of an antibody, and related misadventures in developing an effective treatment for, 302
Sexually transmitted diseases, role of fluoroquinolones in, 189
Sinus arrest associated with continuous-infusion cimetidine, 64
Specialty practice and harmaceutical care, 64S
Split infinitives, 169
Splitting hairs, 169
Suramin, anaphylactoid reaction with, 656

– T –

Template for the evaluation of a clinical pharmacist (ACCP White Paper), 661
The one who dies with the most letters behind his name wins, 519
The strategic plan of the American College of Clinical Pharmacy, 1993, 257
The use of Δ osmolality to predict serum isopropanol and acetone concentrations, 60
Theophylline pharmacokinetics in healthy volunteers, effect of isradipine on, 149

Theophylline, reassessing the therapeutic range for on laboratory report forms: another perspective, 598
Theophylline, reassessing the therapeutic range for on laboratory report forms: another viewpoint, 595
Theophylline, reassessing the therapeutic range for on laboratory report forms: the importance of 5–15 μg/ml, 590
Theophylline, transdermal, evaluation of pharmacokinetics in neonates, 386
Theophylline-propafenone interaction, 68
Therapeutic decisions: assessing clinical fit, 18S
Transdermal theophylline, evaluation of pharmacokinetics in neonates, 386
Treatment and prophylaxis of cytomegalovirus disease: a commentary, 167
Treatment and prophylaxis of cytomegalovirus disease: authors' reply, 168
Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients, 602

– U –

Upper respiratory diseases, pathophysiology and pharmacotherapy of common, 101S
Urinary tract infections in the elderly, 51S
Urinary tract infections, candidal: a comprehensive review of their diagnosis and management, 110

– V –

Vasodilators, diuretics, and angiotensin-converting enzyme inhibitors: assessing the treatment of congestive heart failure, 82S
Verapamil in the elderly, differences in serum concentrations of and responses to generic, 359

– W –

Warfarin and fluconazole, possible interaction between, 508
Whole bowel irrigation (low-volume) and salicylate absorption: a comparison with ipecac-charcoal, 229
Withdrawal syndrome, neonatal: associated drugs and pharmacologic management, 202
Women as research subjects (an ACCP White Paper), 534